Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials

Rigid eligibility criteria exclude stable patients who might benefit from investigational treatments. Easing criteria related to incidental or asymptomatic laboratory abnormalities could broaden trial accessibility and improve enrollment in populations that are more representative of real-world use.